Halozyme Therapeutics Inc
SWB:RV7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Halozyme Therapeutics Inc
SWB:RV7
|
US |
|
I
|
International Container Terminal Services Inc
XPHS:ICT
|
PH |
|
Fuji Electric Co Ltd
F:FJE
|
JP |
|
OneWater Marine Inc
NASDAQ:ONEW
|
US |
|
G
|
General Dynamics Corp
SWB:GDX
|
US |
|
Landis+Gyr Group AG
SIX:LAND
|
CH |
|
Assystem SA
PAR:ASY
|
FR |
|
Loomis AB
F:K900
|
SE |
Intrinsic Value
Is RV7 undervalued or overvalued?
See the intrinsic value estimate for 
Halozyme Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Halozyme Therapeutics Does
Halozyme Therapeutics makes drug-delivery technology that helps injectable medicines move from an IV infusion to a shot under the skin. Its core product is a recombinant enzyme used with partner drugs so patients can receive certain therapies faster and more conveniently in outpatient settings. The company also develops and sells this enzyme in forms used by its pharmaceutical partners and in hospital care.
- Headquarters
- United States of America US
- Employees
- 423
- IPO date
- Jan 30, 2003
Halozyme Therapeutics has a wide economic moat
Patent protection keeps rivals from freely copying Halozyme’s injection technology, while its inclusion in approved medicines makes replacement costly and time-consuming. Together, these barriers help Halozyme retain drug-company partners and collect payments tied to their medicine sales.
Read the full moat analysis
Revenue & Expenses Breakdown
Halozyme Therapeutics Inc
Earnings Waterfall
Halozyme Therapeutics Inc
The intrinsic value for Halozyme Therapeutics Inc (RV7) under the Base Case is hidden EUR.
Compared with the current market price of 93.1 EUR, the stock appears hidden.
